Sydney Stewart, Author at BioTuesdays

Developments

Mackie Research: 2018 Farm Bill leads to misconceptions about what CBD products you can legally sell in U.S.

According to the FDA, the passage of the 2018 Farm Bill has led to the misperception that all products made from or containing hemp, including those made with cannabidiol (CBD), were now legal to sell in interstate...

March 10, 2020

Developments

FDA clears Stereotaxis Genesis robotic magnetic navigation system

Stereotaxis (NYSE:STXS) received FDA 510(k) clearance of the Genesis RMN System for the robotic navigation of magnetic ablation catheters to treat heart rhythm disorders. “Genesis is a leap forward in robotic magnetic...

March 6, 2020

Markets

Echelon ups Extendicare to buy; holds PT at $9

Echelon Wealth Partners upgraded Extendicare (TSX:EXE) to “buy” from “hold” but kept its price target at $9 after the company reported fourth quarter results. The stock closed at $7.85 (Canadian) on March 2. Analyst...

March 3, 2020

Markets

BTIG cuts IMV PT to $5 from $8

BTIG lowered its price target for IMV (NASDAQ, TSX:IMV) to $5 from $8, citing uncertainty about data from the company’s ongoing Phase 2 study of DPX-Survivac in patients with advanced recurrent ovarian cancer. The stock...

February 28, 2020

Markets

WB starts Precision BioSciences at buy; fair value estimate $20

William Blair launched coverage of Precision BioSciences (NASDAQ:DTIL) with an “outperform” rating and fair value estimate of $20. The stock closed at $8.01 on Feb. 24. Precision has pioneered the development of its...

February 25, 2020

Markets

HCW cuts ReWalk Robotics PT to $3.50 from $9

H.C. Wainwright lowered its price target for ReWalk Robotics (NASDAQ:RWLK) to $3.50 from $9, reflecting dilution from a recent public offering. The stock closed at 81 cents on Feb. 20. As a result of the financing, the...

February 21, 2020

Markets

AGP ups Sensus Healthcare to buy; PT $6

Alliance Global Partners upgraded Sensus Healthcare (NASDAQ:SRTS) to “buy” from “neutral” with a price target of $6 after the company reported fourth quarter results. The stock closed at $4.62 on Feb. 13. Analyst Ben...

February 14, 2020

Developments

Titan Pharma’s Probuphine listed on additional provincial drug plans in Canada

Five additional publicly-funded provincial drug plans in Canada are adding Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant to their drug benefits coverage in the fight against the opioid crisis. The provinces of...

February 12, 2020

Developments

Bee Vectoring completes successful registration trials for commercialization in Mexico

Bee Vectoring Technologies International (TSXV:BEE; OTCQB:BEVVF) completed three official registration trials of its Clonostachys rosea CR-7 biological fungicide on commercial strawberry and tomato crops in Mexico...

February 12, 2020

Markets

Maxim starts Heat Biologics at buy; PT $1

Maxim Group launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and price target of $1. The stock closed at 26 cents on Feb. 5. Heat is developing lead asset, ImPACT, a cell-based immune therapy for...

February 6, 2020

Author - Sydney Stewart

Mackie Research: 2018 Farm Bill leads to misconceptions about what CBD products you can legally sell in U.S.

FDA clears Stereotaxis Genesis robotic magnetic navigation system

Echelon ups Extendicare to buy; holds PT at $9

BTIG cuts IMV PT to $5 from $8

WB starts Precision BioSciences at buy; fair value estimate $20

HCW cuts ReWalk Robotics PT to $3.50 from $9

AGP ups Sensus Healthcare to buy; PT $6

Titan Pharma’s Probuphine listed on additional provincial drug plans in Canada

Bee Vectoring completes successful registration trials for commercialization in Mexico

Maxim starts Heat Biologics at buy; PT $1

Subscribe